SEPTRALU registry of 177-Lu-DOTATATE in neuroendocrine tumors: Data from 321 patients in clinical practice

#3312

Introduction: Peptide receptor radionuclide therapy (PRRT) has a phase 3 clinical trial in advanced midgut neuroendocrine tumors (NETs) and clinical practice evidence in other locations.

Aim(s): Describe the characteristics of patients with advanced NETs treated with 177Lu-DOTATATE and analyse the effectiveness and predictive factors.

Materials and methods: The data come from the SEPTRALU, national multicenter database in which multidisciplinary team of 21 centers are participating. Survival was evaluated using the Kaplan-Meier method and the effects of the predictor variables upon survival using Cox proportional hazards regression model.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Mitjavila Casanovas M, Bello P, Pubul V, Arbizu J, Gajate P,

Keywords: 177Lu-DOTATATE, neuroendocrine tumor, peptide receptor radionuclide therapy,